From: Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers
Tumor status | N (Cases) | Prolactin levels (ng/mL) | p-heterogeneity | |
---|---|---|---|---|
≤ 11 | > 11 | |||
All breast cancer | 168 | 1 (Ref) | 1.22 (0.85, 1.73) | Â |
Prolactin receptor | ||||
 Nucleara | ||||
  Negative | 134 | 1 (Ref) | 1.24 (0.84, 1.83) | 0.92 |
  Positive | 29 | 1 (Ref) | 1.19 (0.54, 2.60) | |
 Cytoplasmica | ||||
  Negative | 128 | 1 (Ref) | 1.37 (0.92, 2.05) | 0.22 |
  Positive | 35 | 1 (Ref) | 0.84 (0.42, 1.69) | |
pSTAT5 | ||||
 Nucleara | ||||
  Negative | 117 | 1 (Ref) | 0.98 (0.65, 1.46) | 0.06 |
  Positive | 35 | 1 (Ref) | 2.30 (1.02, 5.22) | |
 Cytoplasmicb | ||||
  Negative | 61 | 1 (Ref) | 0.73 (0.43, 1.25) | 0.02 |
  Positive | 91 | 1 (Ref) | 1.64 (1.01, 2.65) | |
 Combined nuclear/cytoplasmic | ||||
  Both negative | 56 | 1 (Ref) | 0.73 (0.42, 1.28) | 0.03 |
  Both positive | 30 | 1 (Ref) | 2.88 (1.14, 7.25) | |
  One negative/one positive | 66 | 1 (Ref) | 1.24 (0.72, 2.12) | |
pJAK2b | ||||
 Negative | 20 | 1 (Ref) | 1.72 (0.64, 4.65) | 0.49 |
 Positive | 127 | 1 (Ref) | 1.20 (0.80, 1.78) |